Where Interleukin-1 (IL-1α/β) is reported
Also listed as: Interleukin-1α (IL-1α); Pro-inflammatory cytokine
| Condition | Direction | Compared against | Associated symptoms | Source |
|---|---|---|---|---|
| Long COVID | ↑ elevated | healthy controls, recovered individuals without persistent symptoms | Systemic inflammation | Saito et al. 2024 |
| ME/CFS | ↑ elevated | healthy controls | Immune activation, fatigue | Corbitt et al. 2019 |
Frequently asked questions
In which conditions is Interleukin-1 (IL-1α/β) altered?
In the OSMF atlas Interleukin-1 (IL-1α/β) is reported in Long COVID, ME/CFS. It is elevated in 2 across 2 entries.
Does Interleukin-1 (IL-1α/β) point to one specific diagnosis?
No. Because Interleukin-1 (IL-1α/β) changes in several conditions (Long COVID, ME/CFS), an abnormal result cannot identify which condition, if any, is present. It must be interpreted with symptoms, history and other tests.
What is the LOINC code for Interleukin-1 (IL-1α/β)?
Entries in this atlas use LOINC 33821-0, 34407-7. LOINC codes identify the laboratory observation so results can be compared across systems.
Is one abnormal Interleukin-1 (IL-1α/β) result diagnostic?
No single biomarker result is diagnostic of any of these conditions. Findings reflect group averages from published cohorts with substantial overlap between patients and controls.
Cite this page
Disclaimer: Educational synthesis of peer-reviewed research; not medical advice. Findings are group-level and vary with study design. Discuss any result with a qualified clinician.